Collaborative Arrangements and Licensing Agreements, Research, Development and Commercialization Partners - Kastle Therapeutics (Details) - Kastle Therapeutics [Member] - Agreement Entered into in April 2016 [Member] - Kynamro [Member] - Subsequent Event [Member] $ in Millions	May. 04, 2016 USD ($)
Collaborative Arrangement and Licensing Agreement [Abstract]
Maximum amount of payments receivable	$ 95
Upfront payment	15
Next potential payment	$ 10
Ownership interest percentage	10.00%
Royalty percentage earned by Sanofi Genzyme	3.00%
Percentage of payments received from Kastle to be paid to Sanofi Genzyme	3.00%
Commercialization Milestones [Member]
Collaborative Arrangement and Licensing Agreement [Abstract]
Maximum amount of payments receivable	$ 70